PPT-Anticoagulation in Atrial

Fibrillation Michelle Tsukamoto DSR 2 May 9 2018 PGY 2 1 Objectives Discuss which patients with atrial fibrillation should be anticoagulated for CVA prevention Learn about different oral anticoagulation options . Martha Drake MS, FNP-BC. Chicago Heart and Vascular Consultants, LTD. Purdue Northwest Doctorate of Nursing Program. Learning Objectives. Discuss the incidence of atrial fibrillation (AF) in the population. . John Windle MD October 18, 2013. Professor and Chief of Cardiology. University of Nebraska Medical Center. “Ha . ha. . ha. , Biff. Guess what? After we go to the drugstore and the post office, . Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Jennie Hsu-. Lumetta. , MD, FACP. Corinne Kohler, . MD, FAAFP. Narain. . Mandhan. , MD, FACP, FASAM. Karen . Wiarda. , . DO. Muhammad . Ajmal. , . MD, PGY 3 Chief. ACP QI . Project. Atrial Fibrillation . TAVI with atrial fibrillation : which antithrombotic regimen? G. Montalescot (Paris, FR) www.action-cœur.org Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France A ssessment of D ual antiplatelet therapy versus R ivaroxaban I n atrial F ibrillation patients T reated with left atrial appendage closure ADRIFT investigators DOI public at www.action-coeur.org <1% of individuals aged 60 to 65 years . 8% to 10% of individuals aged >80 years . Men more than women . White persons more than black persons. Presence and severity of underlying heart disease increases risk . R. ivaroxaban . I. n atrial . F. ibrillation patients . T. reated with left atrial appendage closure. ADRIFT . investigators. DOI public at www.action-coeur.org. Healing: 30 . days. to 3 . months. Kar et al. JACC Intv 2014;7:801-9. www.RxFiles.ca June 2021 Drug / BRAND Vitamin K Antagonist DOACs Comments There is a positive correlation between warfarin Clair . Huckerby. Pharmaceutical Adviser- Medicines Optimisation . Lead. Dudley CCG. Our mission. To improve the . health and wellbeing . of the . population . of . Dudley . through the . safe and effective . Wessex. A report for Wessex AHSN ‘Atrial Fibrillation: Detect, Perfect, Protect’ . Programme. Dr . Anastasios. Argyropoulos. Centre for Implementation Science. A.Argyropoulos@soton.ac.uk . Wessex. Figure 1 ). Management TheappropriatemanagementofAFisdependentupontheclinicalcontextinwhichitisencountered.Themajorityofcasescanbedealtwithappropriatelyonanoutpatientbasis.TheapproachtothetreatmentofA Guidelines for Clinical Care Inpatient Atrial Fibrillation Guideline TeamTeam MembersJeffrey M Rohde(Team Lead)Internal MedicineSarah E Hartley, MDInternal MedicineSarah Hanigan, PharmDPharmacy Servic - The NOAH-AFNET 6 trial -. Nina Becher, Tobias Toennis, Emanuele Bertaglia, Carina Blomstrom-Lundqvist, Nuno Cabanelas, Melanie Calvert, A John Camm, Gregory Chlouverakis, Gheorghe-Andrei Dan, Wolfgang Dichtl, Hans Christoph Diener, Alexander...